Present posts: NIHR Research Professor，Professor of Urological Surgery at the University of Sheffield , Editor in Chief, European Urology (Impact factor 20.1).

Qualifications:  MB ChB   Leeds University

                        FRCS      Royal College of Surgeons of England

                        PhD     University of Sheffield

Trial activity:

  -Chief Investigator: BRAVO, LABC, IROC, INSTIL, NIAGARA, THOR-2

Prizes awarded:

 -BAUS: Karl Storz Golden Telescope James Catto, BAUS Annual meeting, 2014

 -1st Prize: Challenge the experts: James Catto, European Urology Forum 2011

 -Crystal Matula: James Catto, EAU, Barcelona, 2010

Recent key publications: 

1.Catto JWF … and Kelly JD for the iROC study team. Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs. open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer: a randomized clinical trial. JAMA. 2022 Jun 7;327(21):2092-2103

2.Hussain SA, … Catto JWF, Powles T, Jones RJ. Neoadjuvant trial of Nintedanib or placebo with Gemcitabine and Cisplatin in locally advanced muscle invasive bladder cancer (NEOBLADE): A Randomized double blind Phase II trial. Lancet Oncology 2022: In press

3.Catto JWF et al. Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes. Eur Urol. 2021 May;79(5):621-632

4.Catto JWF et al. Radical Cystectomy against intra-vesical BCG for high-grade non-muscle invasive bladder cancer. J Clin Oncol 2021:39(3):202-14 (IF 32.956)

5.Crabb SJ, Danson S, Catto JWF, et al. Phase I trial of DNA methyltransferase inhibitor guadecitabine (SPIRE). Clin. Cancer Res. 2021 Apr 1;27(7):1882-1892.